Vectus Biosystems (ASX:VBS) Total Liabilities : A$0.83 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Total Liabilities?

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2024 was A$0.83 Mil.

Vectus Biosystems's quarterly Total Liabilities declined from Dec. 2023 (A$0.84 Mil) to Jun. 2024 (A$0.54 Mil) but then increased from Jun. 2024 (A$0.54 Mil) to Dec. 2024 (A$0.83 Mil).

Vectus Biosystems's annual Total Liabilities declined from Jun. 2022 (A$7.47 Mil) to Jun. 2023 (A$1.11 Mil) and declined from Jun. 2023 (A$1.11 Mil) to Jun. 2024 (A$0.54 Mil).

Vectus Biosystems Total Liabilities Historical Data

The historical data trend for Vectus Biosystems's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Total Liabilities Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

8.64

8.87

7.47

1.11

0.54

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial													1.02	1.11	0.84	0.54	0.83

Vectus Biosystems Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vectus Biosystems's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.535	+	(0	+	-0.001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.005	+	0)
	=	0.54

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	2.026	-	1.486
	=	0.54

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.829	+	(0	+	0.002
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.83

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1.234	-	0.403
	=	0.83

Vectus Biosystems Total Liabilities Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines